ClinicalTrials.gg
CompletedNCT03961295Updated Nov 13, 2019Results posted

A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

A Phase 1 interventional study of Vedolizumab SC in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-13.

Sponsored by Takeda · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Feb 2018, registered May 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to compare PK of single dose of vedolizumab SC 108 milligram (mg) administered as PFS vs investigational device.

Read the detailed description

The drug being tested in this study is called vedolizumab SC. The study will assess the PK, and variability of a vedolizumab SC in a PFS vs investigational device.

This study will include 2 different device delivery presentations in 2 treatment groups. Participants in each treatment group will be randomized to one of the three administration sites: Abdomen, thigh, or arm. The study will enroll approximately 24 participants, including 4 participants allocated to each administration site within each treatment group. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups:

  • Group A: Vedolizumab SC PFS
  • Group B: Vedolizumab SC Investigational Device

All participants will receive a single dose of study drug on Day 1.

This single center trial will be conducted in the United States. The overall time to participate in this study is approximately 196 days. Participants will be contacted by telephone on Day 168 after their last dose of study drug for a follow-up assessment which will involve the progressive multifocal leukoencephalopathy (PML) questionnaire survey.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Drug therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Weighs greater than (>) 50 kilogram (kg) and less than (\<) 90 kg and has a (BMI) from 18 to 28 kilogram per square meter (kg/m\^2), inclusive, at the time of .

Exclusion criteria

Exclusion Criteria:

  1. Has received any or approved biologic or biosimilar within 30 days or 5 half-lives, of Screening, whichever is longer.
  2. Has had prior exposure to vedolizumab, or has to vedolizumab or any of its components.
  3. Has had previous exposure to approved or investigational anti-integrins (example, natalizumab, efalizumab, etrolizumab, AMG 181) or anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibodies or rituximab.
  4. Has 1 or more positive responses on the PML subjective symptom checklist at screening or before dosing on Day 1.
  5. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year before the Screening Visit or is unwilling to agree to abstain from alcohol for 7 days before Day -1 throughout confinement and for 48 hours before each clinic visit; and drugs throughout the study.
  6. Has evidence of an active infection during the Screening Period.
  7. Has received any within 30 days before Screening.
  8. Has active or latent tuberculosis (TB) as evidenced by the following:

    o A diagnostic TB test performed within 30 days of Screening or during the Screening Period that is positive, defined as:

    1. Positive QuantiFERON test or 2 successive indeterminate QuantiFERON tests, OR
    2. A TB skin test reaction greater than or equal to (>=) 5 millimeter (mm). NOTE: If participants have received Bacillus Calmette-Guerin (BCG) vaccine then a QuantiFERON TB Gold test should be performed instead of the TB skin test.

    Note: Participants with documented previously treated TB with a negative QuantiFERON test can be included in the study.

  9. Has poor peripheral venous access.
  10. Is unable to attend all the study visits or comply with study procedures.
  11. Has donated or lost 450 milliliter (mL) or more of his or her blood volume (including serum pheresis), or had a transfusion of any blood product within 45 days before Day 1.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Group A: Vedolizumab SC PFS

    Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.

    Drug: Vedolizumab SC

  • Experimental
    Group B: Vedolizumab SC Investigational Device

    Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.

    Drug: Vedolizumab SC

Interventions

  • Vedolizumab SC liquid.

    Also known as: ENTYVIO, KYNTELES, MLN0002

06

What researchers measure

Primary outcomes

  1. AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vedolizumab SC

    Time frame: Day 1 pre-dose and at multiple time points (up to Day 127) post-dose

  2. AUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for Vedolizumab SC

    Time frame: Day 1 pre-dose and at multiple time points (up to Day 127) post-dose

  3. Cmax: Maximum Observed Serum Concentration for Vedolizumab SC

    Time frame: Day 1 pre-dose and at multiple time points (up to Day 127) post-dose

07

Results

Posted Aug 19, 2019

Participant flow

Participants took part in the study at 1 investigative site in the United states from 22 February 2018 to 28 August 2018.

Participant flow — Overall Study
MilestoneGroup A: Vedolizumab SC PFSGroup B: Vedolizumab SC Investigational Device
Started1212
Completed1212
Not completed00

Outcome measures

PrimaryAUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vedolizumab SC
Time frame:
Day 1 pre-dose and at multiple time points (up to Day 127) post-dose
Reported as:
Geometric mean · microgram*day per milliliter(mcg*day/mL)
AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vedolizumab SC
microgram*day per milliliter(mcg*day/mL)Group A: Vedolizumab SC PFSGroup B: Vedolizumab SC Investigational Device
AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vedolizumab SC433.4 ± 38.3560.3 ± 26.3
Statistical analysis
  • Group A: Vedolizumab SC PFS vs Group B: Vedolizumab SC Investigational Device · Ratio of geometric lsms: 1.2984 · 90% CI 1.0786 to 1.5486
PrimaryAUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for Vedolizumab SC
Time frame:
Day 1 pre-dose and at multiple time points (up to Day 127) post-dose
Reported as:
Geometric mean · mcg*day/mL
AUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for Vedolizumab SC
mcg*day/mLGroup A: Vedolizumab SC PFSGroup B: Vedolizumab SC Investigational Device
AUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for Vedolizumab SC446.5 ± 36.2594.0 ± 23.6
Statistical analysis
  • Group A: Vedolizumab SC PFS vs Group B: Vedolizumab SC Investigational Device · Ratio of geometric lsms: 1.3274 · 90% CI 1.1147 to 1.5807
PrimaryCmax: Maximum Observed Serum Concentration for Vedolizumab SC
Time frame:
Day 1 pre-dose and at multiple time points (up to Day 127) post-dose
Reported as:
Geometric mean · microgram per milliliter (mcg/mL)
Cmax: Maximum Observed Serum Concentration for Vedolizumab SC
microgram per milliliter (mcg/mL)Group A: Vedolizumab SC PFSGroup B: Vedolizumab SC Investigational Device
Cmax: Maximum Observed Serum Concentration for Vedolizumab SC13.70 ± 24.216.53 ± 26.9
Statistical analysis
  • Group A: Vedolizumab SC PFS vs Group B: Vedolizumab SC Investigational Device · Ratio of geometric lsms: 1.1978 · 90% CI 1.0394 to 1.3804

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) are adverse events that started after the first dose of study drug and no more than Day 127. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A: Vedolizumab SC PFS0/12 (0%)1/12 (8.3%)9/12 (75%)
Group B: Vedolizumab SC Investigational Device0/12 (0%)0/12 (0%)6/12 (50%)
Most frequent serious events
Most frequent serious events
EventGroup A: Vedolizumab SC PFSGroup B: Vedolizumab SC Investigational Device
PneumoniaInfections and infestations1/120/12
Most frequent other events
Showing 10 of 16
Most frequent other events
EventGroup A: Vedolizumab SC PFSGroup B: Vedolizumab SC Investigational Device
Injection site painGeneral disorders6/123/12
Upper respiratory tract infectionInfections and infestations2/123/12
HeadacheNervous system disorders1/122/12
Abdominal painGastrointestinal disorders0/121/12
DyspepsiaGastrointestinal disorders1/120/12
Injection site paraesthesiaGeneral disorders1/120/12
EpididymitisInfections and infestations1/120/12
PneumoniaInfections and infestations0/121/12
Urinary tract infectionInfections and infestations0/121/12
Vaginal infectionInfections and infestations0/121/12

Baseline characteristics

The safety analysis set included all participants who were enrolled and received 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Group A: Vedolizumab SC PFSGroup B: Vedolizumab SC Investigational DeviceTotal
Mean37.2 ± 13.5533.6 ± 12.5235.4 ± 12.89
Sex: Female, Male
Sex: Female, Male(Participants)Group A: Vedolizumab SC PFSGroup B: Vedolizumab SC Investigational DeviceTotal
Female6612
Male6612
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group A: Vedolizumab SC PFSGroup B: Vedolizumab SC Investigational DeviceTotal
Hispanic or Latino112
Not Hispanic or Latino111122
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group A: Vedolizumab SC PFSGroup B: Vedolizumab SC Investigational DeviceTotal
American Indian or Alaska Native101
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American134
White10717
More than one race011
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Group A: Vedolizumab SC PFSGroup B: Vedolizumab SC Investigational DeviceTotal
United States121224
Weight
Weight(kilogram (kg))Group A: Vedolizumab SC PFSGroup B: Vedolizumab SC Investigational DeviceTotal
Mean71.35 ± 11.61469.26 ± 10.63770.30 ± 10.944
Height
Height(centimeter (cm))Group A: Vedolizumab SC PFSGroup B: Vedolizumab SC Investigational DeviceTotal
Mean170.4 ± 10.08171.0 ± 7.94170.7 ± 8.88
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))Group A: Vedolizumab SC PFSGroup B: Vedolizumab SC Investigational DeviceTotal
Mean24.558 ± 3.238123.603 ± 2.723224.080 ± 2.9663
08

Study locations

1 site
  • Celerion
    Lincoln, Nebraska 68502, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Jul 2018, 4 months.

Results were first posted in Aug 2019, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2019
First posted
May 23, 2019
StartActual
Feb 22, 2018
Primary completionActual
Jul 14, 2018
CompletionActual
Aug 28, 2018
Results first posted
Aug 19, 2019
Last update
Nov 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03961295
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
May 23, 2019
Start date
Feb 22, 2018
Primary completion
Jul 14, 2018
Completion
Aug 28, 2018
Results posted
Aug 19, 2019
Last update
Nov 13, 2019

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion